Core Viewpoint - The article emphasizes the development of the biomanufacturing industry in Hubei Province, which is seen as a key future industry as outlined in the 2025 government work report, aiming to transform small microorganisms into large-scale industries [1]. Group 1: Agricultural Biomanufacturing - Hubei Fubon Technology Co., Ltd. is focusing on innovative agricultural biopreparations, developing new biodegradable coating agents and soil restoration agents to enhance grain yield [2]. - The company's core product, "biostimulants," acts as a "lubricant" and "amplifier" in agricultural production, improving the efficiency of pesticides and fertilizers [4]. - The research team led by Professor Chen Shouwen from Hubei University has developed a biostimulant using Bacillus licheniformis, showcasing advantages in bioprocessing and broad applications [4]. Group 2: Industrial Microbial Strains - Industrial microbial strains are considered the "chips" of biomanufacturing, with over 80% of core industrial strains in China being dependent on foreign sources [6]. - Research on the strain "Pseudomonas putida" has shown its potential to convert agricultural waste into ethanol, presenting a sustainable alternative to traditional methods that rely on food crops [8]. - Wuhan Ruijia Kang Biotechnology Co., Ltd., founded by Professor Yang Shihui, has developed cellulose ethanol and D-lactic acid, with plans to achieve a production scale of 100,000 tons within five years [8]. Group 3: Collaborative Innovation - Hubei Province is building a collaborative system involving government, industry, academia, and finance to accelerate the development of biomanufacturing [9]. - Hubei University has established partnerships with companies like Angel Yeast to create a joint innovation platform for synthetic biology and modern biomanufacturing [10]. - The provincial government is addressing technology demands across various sectors to promote high-quality development in the synthetic biology industry during the 14th Five-Year Plan [12].

Core Viewpoint - Evonik announced plans to optimize the global production layout of MetAMINO® (DL-methionine) in the third and fourth quarters of 2025, including temporary shutdowns of production facilities in Singapore and Antwerp to enhance energy efficiency and reduce CO2 emissions [1][4]. Group 1: Production Capacity and Market Dynamics - The global methionine production capacity is projected to reach 2.35 million tons per year by 2024, with Evonik, Adisseo, and Sinochem accounting for 71% of this capacity [4]. - China's methionine production capacity is expected to reach 840,000 tons per year by the end of 2024, representing 36% of the global total, with further expansion anticipated to exceed 1.2 million tons by 2029 [5][6]. - China has transitioned from a net importer to a net exporter of methionine, with a projected consumption of 430,000 tons in 2024, including 160,000 tons imported and 410,000 tons exported, resulting in a net export of 250,000 tons [6]. Group 2: Production Methods and Innovations - Biotechnological methods for producing methionine offer advantages over chemical methods, including higher efficiency and reduced safety risks associated with toxic substances [7]. - The industrialization of biological methionine production has been slow due to low yield during fermentation processes, with only one company, HJ, successfully achieving bulk production [9]. - In China, significant advancements in L-methionine biosynthesis have been made by academic teams, leading to the development of microbial cell factories for efficient precursor synthesis [11][12].

Core Viewpoint - The synthetic biology industry is rapidly developing in China, supported by government policies, and is expected to become a new golden track for investment opportunities [1][2]. Industry Overview - Synthetic biology is recognized as one of the most transformative technologies in the life sciences of the 21st century, with various regions in China, including Shenzhen, prioritizing its development [2]. - The domestic synthetic biology technology sector was in its early stages in 2017, with limited recognition of its application value [2]. Company Profile - Shenzhen Ruidelin Biotechnology Co., Ltd. focuses on synthetic biology technology and has developed over 200 patents related to biosynthetic active ingredients, serving more than 2,000 enterprises [1][3]. - The company aims to address industry pain points by utilizing biosynthetic technology to reduce costs and increase production capacity for peptides [2][3]. Technological Innovation - Ruidelin has established a multidisciplinary green biotechnology manufacturing platform that integrates various engineering disciplines, enhancing research and development efficiency [4]. - The company has incorporated artificial intelligence into enzyme engineering, creating over 50 AI models to optimize enzyme performance, which significantly improves research efficiency [5]. Production Capacity - Ruidelin has invested nearly 200 million yuan to build a green active ingredient smart factory, which includes two hundred-ton production lines and has successfully scaled up production of various products [7]. - The company is constructing a thousand-ton production base in Shaoguan, Guangdong, expected to produce over 1,000 tons of green active ingredients annually, generating more than 2 billion yuan in annual output value [7]. Financial Performance - Since 2022, Ruidelin has experienced continuous revenue growth, with projected revenue exceeding 100 million yuan in 2024 [8].

Core Insights - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a program to cultivate over 20 pilot platforms for biomanufacturing by 2027, aiming to facilitate industrial scale-up [1] - Significant technological breakthroughs and industrial layouts are emerging in the biomanufacturing sector, with advancements in areas such as polysulfone plastic recycling and wool sterol synthesis [1] - The synergy between policy support and industrial development is accelerating the transition of biomanufacturing from laboratory research to large-scale industrialization, showcasing a vibrant development chain of "technological breakthroughs - policy support - capital influx" [1] Industry Developments - Synthetic biology is reshaping production models in biomanufacturing, enabling tasks that traditional biotechnologies cannot achieve, while also providing more efficient and environmentally friendly biosynthesis solutions [1] - Companies like Huaxi Biological and Yikole are extending their capabilities in synthetic biology, with Huaxi focusing on the supply chain of hyaluronic acid and Yikole leveraging CRISPR-Cas9 technology for precise gene editing [2][3] - The integration of synthetic biology with traditional industries is seen as a means to enhance productivity and create new growth opportunities, rather than a conflict [4] Technological Innovations - Companies are developing comprehensive systems in synthetic biology, focusing on tool, platform, and product integration, with significant advancements in production efficiency [3] - AI is playing a crucial role in enhancing research efficiency in synthetic biology, with companies establishing AI teams to optimize data collection and algorithm development [7] - The use of AI in the design and testing phases of synthetic biology is expected to significantly reduce research timelines and costs, improving overall productivity [7] Market Trends - The biomanufacturing industry is experiencing a wave of policy support, with various local governments implementing initiatives to promote the industrialization of synthetic biology [8] - The market for biomanufacturing in China is projected to approach 1.8 trillion yuan by 2030, indicating substantial growth potential [8] - Recent financing trends show an acceleration in investments in domestic synthetic biology companies, with nearly a hundred firms securing new funding at the beginning of 2025 [8] Future Outlook - The synthetic biology sector is anticipated to undergo rapid technological iterations and deeper application expansions in the next 3-5 years, driven by AI advancements [9] - Companies are encouraged to focus on quality improvement and original design rather than mere scale expansion, to avoid resource wastage and industry chaos [9] - The industry is expected to face dual challenges in technology transfer and industrialization, particularly in constructing microbial cell factories and overcoming engineering challenges in fermentation and purification [10]

Investment Rating - The report rates the investment outlook for the medical beauty regenerative anti-aging injection industry as "Positive" [5] Core Insights - The regenerative anti-aging injection agents are emerging materials that achieve facial rejuvenation through different mechanisms compared to hyaluronic acid and botulinum toxin [1] - The midstream of the regenerative anti-aging injection industry chain is identified as the segment with the highest added value, supported by regulatory compliance, technological innovation, and market demand [2] - Future trends in the industry include increased demand driven by an aging population, a shift towards non-surgical aesthetic procedures, and advancements in technology and materials that enhance product efficacy [3] Summary by Sections 1. Overview of the Medical Beauty Regenerative Anti-Aging Injection Industry - Medical beauty injection products are categorized into hyaluronic acid, botulinum toxin, and regenerative anti-aging materials, with the latter being newly introduced in the domestic market [11] - Regenerative anti-aging injections include subclasses such as microsphere regeneration, collagen, and PDRN, each with distinct mechanisms and benefits [12][13] 2. Industry Chain Analysis - The midstream segment is characterized by high added value, with companies leveraging compliance, innovation, and production capabilities to establish competitive barriers [2][29] - The upstream involves raw material suppliers, while the downstream focuses on the distribution to end consumers through various channels [26] 3. Regulatory and Policy Environment - The industry is regulated by key agencies including the National Health Commission and the National Medical Products Administration, ensuring compliance across all stages from development to sales [43][46] 4. Market Size and Growth Potential - The market for medical beauty injections in China is projected to grow from 21.2 billion RMB in 2023 to 65.3 billion RMB by 2028, with a CAGR of 25.3% [17] - The regenerative anti-aging segment is expected to see a significant increase, with its market share rising from 3% in 2019 to an estimated 31% by 2028 [20] 5. Investment Recommendations - Companies with a comprehensive industry chain layout and a strong product portfolio, such as Jinbo Biological and East China Pharmaceutical, are highlighted as having strong growth potential and investment value [3]

Group 1: Core Insights - The article introduces the "Global Bio-based Industry Monthly Report," providing insights into the latest trends and opportunities in the bio-based sector [1][2][3] - The report is available for free to industry peers, highlighting the importance of collaboration and information sharing within the bio-based industry [1][3] Group 2: Policy Releases - Three domestic bio-based related policies were recorded in May 2025, focusing on carbon reduction projects, including biodegradable polyester rubber and sustainable aviation fuel [7][8] - Key projects include a 110,000-ton biodegradable polyester rubber demonstration project and a 1 million-ton sustainable aviation fuel project [8] Group 3: Industry Dynamics - The report includes updates on domestic bio-based chemical companies, such as the establishment of a lactate production line with an investment of 120 million yuan [9][10] - New companies in the bio-based sector are emerging, such as Yantai Wanhua Chemical, which has launched a new subsidiary focused on food additives [10] Group 4: Capital Events - Several financing events in the bio-based sector were reported, including a B round financing of several million yuan for Senqi New Materials and angel round financing for Zhongke Kexin [11][22] - Notable investments include over 100 million yuan for a recombinant collagen company and nearly 100 million yuan for a bioactive ingredient company [22] Group 5: Scientific Research Progress - Significant breakthroughs in bio-based materials research were highlighted, including the development of a new type of conductive "E-skin" for health sensing applications [12][23] - Research on bioremediation using engineered bacteria to address complex organic pollutants was also reported, showcasing advancements in environmental applications of synthetic biology [23] Group 6: Upcoming Events - The Fourth Synthetic Biology and Green Bio-manufacturing Conference is scheduled for August 20-22, 2025, in Jinan, Shandong, focusing on the future of bio-manufacturing and technology transfer [25][26]

Core Viewpoint - The integration of chemical and biological synthesis is essential for achieving efficient chemical bond activation, cleavage, and reorganization, emphasizing the collaborative potential of both methods [2][4]. Group 1: Chemical and Biological Synthesis - The core goal of chemical-biological synergy is to enhance efficiency and reduce costs by leveraging the strengths of both chemical and biological synthesis methods [2][4]. - Chemical synthesis will not be completely replaced by biological synthesis; instead, the focus is on how to complement each other to create lower-cost and higher-value pathways [4][5]. Group 2: Case Studies and Applications - Examples include the production of artemisinin, where biological synthesis converts sugars to artemisinic acid, while chemical methods enhance production efficiency through hydrogenation and oxidation [6]. - Collaborative efforts in various fields, such as polymer materials and drug development, have shown significant results, indicating a broad application prospect for chemical-biological synergy [6]. Group 3: Advances in Catalysis - Biomimetic catalysis is a key area where chemists learn from biologists, with future developments focusing on the diversity of catalytic systems and synergistic catalytic functions [7]. - Breakthroughs in artificial enzymes and non-natural reactions have been achieved by combining chemical catalysts with protein systems, providing new pathways for complex molecule synthesis [8]. Group 4: Innovations in Synthetic Biology - Combinatorial biosynthesis through genome recombination and editing generates non-natural products, with chemical methods playing a crucial role in precursor provision and subsequent modifications [9]. - The synthesis of nucleic acids, proteins, and carbohydrates faces challenges, but advancements are being made in functionalization and long DNA synthesis [11][12][13]. Group 5: Future Outlook and Technological Integration - AI and big data are poised to play significant roles in promoting the integration of chemical and biological synthesis, accelerating genome mining, molecular design, and synthesis pathway optimization [14]. - The deep-sea scientific program exemplifies the potential for protein and enzyme modification in extreme environments, showcasing innovative research directions [15]. Group 6: Policy and Support for Research - A call for national-level top-level design to promote interdisciplinary research in chemical-biological synergy, particularly supporting young researchers in fields like medicine, materials, energy, and carbon neutrality [16].

Group 1: Policy Release - The report includes three domestic policies related to the bio-based industry released in May 2025, focusing on carbon reduction projects [7][18]. - Key projects include a 110,000-ton biodegradable polyester rubber demonstration project and a 1 million-ton waste oil processing sustainable aviation fuel project [8]. Group 2: Industry Dynamics - The report highlights two domestic bio-based chemical company updates, including a 120 million yuan investment in a lactic acid production demonstration line by Heilongjiang Guoke Bio-based New Materials [9]. - Wanhu Chemical has established a new company focusing on food additives, with a registered capital of 20 million yuan [10]. Group 3: Capital Events - Several financing events in the bio-based sector are reported, including a Series B round raising several million yuan for Senqi New Materials, focusing on bio-based high barrier film materials [11]. - Other notable investments include a multi-million yuan angel round for Zhongke Kexuan, specializing in fully natural degradable plastics [11]. Group 4: Scientific Research Progress - Significant breakthroughs in bio-based materials research are noted, including a study on lignin-derived carbon improving catalytic performance [12]. - Research on bio-inspired reconfigurable electronic skin has been developed, showcasing antibacterial properties for health sensing applications [12]. Group 5: Upcoming Events - The Fourth Synthetic Biology and Green Bio-manufacturing Conference will be held from August 20-22, 2025, in Jinan, Shandong, focusing on the development trends of the bio-manufacturing industry [25].

#全球政策进展 | 上海市 关于上海市2025年度关键技术研发计划"合成生物学"项目拟立项项目的公示 根据市科技计划项目管理办法有关规定，现将上海市2025年度关键技术研发计划"合成生物学"项目拟 立项项目予以公示。 | 图源：上海市科学技术委员会 | | --- | 公示链接：http://svc.stcsm.sh.gov.cn/public/guide 公示期：2025年6月12日至2025年6月18日 对公示内容持有异议的，请于公示期内以书面形式向我委反映。按照市科研失信行为调查处理办法有关 规定，个人提出异议的，请在异议材料上注明姓名和联系电话；单位提出异议的，请在异议材料上加盖 单位公章，并注明联系人和联系电话。我委对异议者的信息予以保密。为保证异议处理客观、公正、公 平，保护被公示者的合法权益，我委对匿名且无明确证据和可查线索的异议，不予受理。 材料寄送至：市科委科技人才处（上海市人民大道200号，邮编200003）。 投诉举报电话：60286858 业务咨询电话：8008205114（座机）、4008205114（手机） 上海市科学技术委员会 2025年6月12日 上海市2025年度关键技术研发 ...

Core Viewpoint - The research highlights the potential of genetically engineered human mesenchymal progenitor cells (SRC) to counteract aging in primates, suggesting a new paradigm for anti-aging cell therapy [2][12]. Group 1: Aging Mechanism and Cell Therapy - The study investigates the mechanisms of aging regulation and employs synthetic biology to reprogram longevity gene pathways, successfully creating SRC with triple resistance to aging, stress, and malignant transformation [3][7]. - SRC cells exhibit significant anti-aging activity and strong environmental adaptability, while also demonstrating excellent safety features to avoid tumorigenic risks post-transplantation [8]. Group 2: Experimental Results - In a 44-week trial involving elderly crab-eating macaques (equivalent to 60-70 years in human age), SRC therapy resulted in reduced systemic aging indicators, such as cellular senescence, chronic inflammation, and tissue degeneration, with no adverse reactions detected [10]. - Notably, SRC treatment improved brain structure and cognitive function, reversing the biological age of immature neurons by 6-7 years and oocytes by 5 years, as confirmed by machine learning-based aging clock analysis [10]. Group 3: Mechanism of Action - The restorative effects of SRC are partially attributed to their exosomes, which play a crucial role in promoting cellular rejuvenation, inhibiting chronic inflammation, and maintaining genomic and epigenomic stability, providing new insights into pathways for delaying systemic aging [10].